The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
When paired with a healthier diet and a consistent diet and exercise program, semaglutide therapy can help people lose stubborn pounds while promoting better blood sugar control and cardiovascular health
Who needs BPC 157
Packages of 10 or 100
All needles are manufactured to strict quality standards using computerized grinding and 100% visual camera inspection to promote sharp, consistent, and high-quality needles in FDA-inspected ISO 13485 certified facilities which utilize good manufacturing practices per USFDA standards
For patients with adequate levels, the injections are unlikely to deliver the dramatic results that marketing materials suggest
